Alternating recombinant and natural alpha-interferon helps to prevent clinical resistance to interferon in cutaneous T-cell lymphoma treatment

Altomare, Gianfranco; Capella, Giovanni Luigi; Frigerio, Elena
May 1998
Acta Dermato-Venereologica;5/1/1998, Vol. 78 Issue 2, p159
Academic Journal
Presents a case report regarding the administration of recombinant alpha interferon for the treatment of cutaneous T-cell lymphoma. Influence of antibodies on alpha interferon efficacy; Synthesis of biologically active alpha interferon-neutralizing endogenous antibodies; Applicability of interferons in treating lymphoproliferate diseases.


Related Articles

  • I Tositumomab: A Viewpoint by Wolfgang Kern. Kern, W. // BioDrugs;2000, Vol. 14 Issue 3, p203 

    Focuses on the improvements made in understanding the pathogenetic basis of various non-Hodgkin's lymphomas. Comparison of the efficacy of different treatment approaches in specific types of lymphomas; Increase in the dose intensity of radiochemotherapy; Introduction of biologically-based...

  • Acute Non--Lymphoblastic Leukemia After Treatment of Nodular Lymphoma with Human Leukocyte Interferon. Warrell Jr., Raymond P.; Krown, Susan E.; Koziner, Benjamin; Andreeff, Michael; Kempin, Sanford J. // Annals of Internal Medicine;Apr83, Vol. 98 Issue 4, p482 

    Presents a case study of a patient with acute non-lymphoblastic leukemia after the treatment of nodular lymphoma with human leukocyte interferon. Medical history of the patient; Results of laboratory examinations; Discussion of the condition.

  • Traitement de maintenance des lymphomes malins non hodgkiniens. Pascal, L.; Terriou, L.; Morschhauser, F. // Oncologie;Sep2011, Vol. 13 Issue 9, p543 

    Maintenance treatment aims to sustain the response of induction chemotherapy, reduce the relapse rate, and provide a longer progression-free survival and time to the next course of chemotherapy. It must have an acceptable toxicity profile in order to obtain the trust of both patient and...

  • Roferon-A.  // Royal Society of Medicine: Medicines;2002, p481 

    The article presents information on roferon-A, a proprietary, prescription-only preparation of interferon. The drug can be used as an anticancer drug in the treatment of hairy cell leukemia, myelogenous leukemia, certain renal cell lymphoma, follicular non-Hodgkin's lymphoma, as an adjunct to...

  • Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma. Herold, Michael; Scholz, Christian; Rothmann, Frank; Hirt, Carsten; Lakner, Volker; Naumann, Ralph // Journal of Cancer Research & Clinical Oncology;Sep2015, Vol. 141 Issue 9, p1689 

    Purpose: The randomised, controlled OSHO#39 study showed promising results using first-line mitoxantrone, chlorambucil and prednisolone (MCP) chemotherapy plus rituximab in patients with advanced symptomatic follicular lymphoma (FL) in need of therapy. The aim of this long-term follow-up was to...

  • Transgene presents positive phase I/II data for adeno-interferon gamma product in cutaneous lymphoma.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p24 

    Reports on Transgene's announcement of positive results from its phase I/II clinical trial of its immunotherapy product candidate ad-IFN gamma in patients with primary cutaneous lymphoma. Presentation of study data at the cancer clinical trials session of the 6th Annual Meeting of the American...

  • Progress in Radioimmunotherapy. Bast, Robert C. // New England Journal of Medicine;10/21/93, Vol. 329 Issue 17, p1266 

    Editorial. Discusses the use of monoclonal techniques in clinical oncology. Non-Hodgkin's lymphoma as an appealing target for monoclonal serologic therapy in vivo; Article by Press, et al, in the October 21, 1993 issue of the `New England Journal of Medicine' dealing with the treatment of...

  • Clinical Trials Explore New. Guttman Strategies for Treatment of CTCL, Cheryl // Dermatology Times;Jul98, Vol. 19 Issue 7, p32 

    Presents several therapeutic approaches for the treatment of cutaneous T-cell lymphoma. Vaccination method to kill T-cells which causes the disease; Treatment with cytokine therapy to restore immune function; Topical application of retinoids.

  • Gastric lymphomas: Before and after. Schmutz, Donald A.; R.M.D. // Cortlandt Forum;6/25/95, Vol. 8 Issue 6, p94 

    Inquires about the preoperative treatment required for an extensive superficial lymphoma that requires total gastrectomy. Increase in frequency of gastric lymphoma; Chemotherapy or radiation as not helpful preoperative treatment; Reference reading.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics